Signed in as:
filler@godaddy.com
Publications
An Ongoing Commitment to Research and Innovation
Intralesional rhEGF is a well-established therapeutic agent with a solid foundation of more than three decades of research and development.
The robust pedigree of intralesional rhEGF continues to expand through ongoing contributions to scientific publications.
Exploratory Research
Wound healing promotion in rats treated with EGF is dose dependent
Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases
The effect of the EGF treatment schedule on the healing process of full-thickness wounds in pigs
The effect of the EGF treatment schedule on the healing process of full-thickness wounds in pigs
Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases
The effect of the EGF treatment schedule on the healing process of full-thickness wounds in pigs
Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases
Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases
Epidermal growth factor stimulated re-epithelialization in pigs: The possible role of acute wound proteases
International Clinical Development & Studies
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional injections of Citoprot-P (recombinant human epidermal growth factor) in advanced diabetic foot ulcers with risk of amputation
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional administration of EGF-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure
Intralesional injections of rhEGF promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomized, placebo-controlled, double-blind study
Intralesional administration of EGF-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure
Systemic translation of locally infiltrated epidermal growth factor in diabetic lower extremity wounds
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Intralesional administration of EGF-based formulation (Heberprot-P) in chronic diabetic foot ulcer: treatment up to complete wound closure
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Diabetic Foot Ulcers and Epidermal Growth Factor: Revisiting the Local Delivery Route for a Successful Outcome
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Epidermal Growth Factor Therapy Impact on Scar Tissue Resilience of Diabetic Lower Limbs Ulcers-An Enlightening Hypothesis
Epidermal Growth Factor based Therapy Promotes Intracellular Trafficking and Accumulation of its Receptor in the Nucleus of Fibroblasts from Diabetic Foot Ulcers
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Epidermal Growth Factor based Therapy Promotes Intracellular Trafficking and Accumulation of its Receptor in the Nucleus of Fibroblasts from Diabetic Foot Ulcers
Diabetic lower extremity wounds: the rationale for growth factors-based infiltration treatment
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Epidermal Growth Factor based Therapy Promotes Intracellular Trafficking and Accumulation of its Receptor in the Nucleus of Fibroblasts from Diabetic Foot Ulcers
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Epidermal growth factor in clinical practice - a review of its biological actions, clinical indications and safety implications
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
Epidermal Growth Factor (EGF) and Platelet-Derived Growth Factor (PDGF) as Tissue Healing Agents: Clarifying Concerns about their Possible Role in Malignant Transformation and Tumor Progression
Endogenous Biological Drivers in Diabetic Lower Limb Wounds Recurrence: Hypothetical Reflections
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
Granulation response and partial wound closure predict healing in clinical trials on advanced diabetes foot ulcers treated with recombinant human epidermal growth factor
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.